Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1931-1935

  Henrich, Timothy J ^a,b   Lewine, Nicolas R P ^c   Lee, Sun Hee ^a,b,d   Rao, Suhas S P ^c   Berro, Reem ^e   Gulick, Roy M ^e   Moore, John P ^e   Tsibris, Athe M N ^a,b   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d Pusan National University   (South Korea)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CHEMOKINE RECEPTOR CCR5; MONOCLONAL ANTIBODY; VICRIVIROC;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL HETEROGENEITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS MUTATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; TRIAZOLES;

EID: 84863363083     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06061-11     Document Type: Article

References (28)

1. Anastassopoulou CG, et al. 2011. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology 413:47-59.
2. Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. 2009. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 5:e1000548.
3. Cocchi F, et al. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1244-1247. (Pubitemid 26375410)
4. Cormier EG, Dragic T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76:8953-8957. (Pubitemid 34864089)
5. Gonzalez E, et al. 1999. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. U. S. A. 96:12004-12009. (Pubitemid 29502848)
6. Gulick RM, et al. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 196:304-312. (Pubitemid 47047471)
7. Henrich TJ, et al. 2010. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J. Acquir. Immune Defic. Syndr. 55:420-427.
8. Huang CC, et al. 2007. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317: 1930-1934.
9. Huang CC, et al. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
10. Kirchherr JL, et al. 2007. High throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Methods 143:104-111. (Pubitemid 46813163)
11. Kuhmann SE, et al. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78:2790-2807. (Pubitemid 38314338)
12. Lin NH, et al. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J. Virol. Methods 169:39-46.
13. Marozsan AJ, et al. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338:182-199. (Pubitemid 40835936)
14. Martin MP, et al. 1998. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-1911.
15. McNicholas PM, et al. 2011. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J. Acquir. Immune Defic. Syndr. 56:222-229.
16. McNicholl JM, Smith DK, Qari SH, Hodge T. 1997. Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele (delta 32 CCR5). Emerg. Infect. Dis. 3:261-271. (Pubitemid 127431686)
17. Ogert RA, et al. 2009. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J. Virol. 83:12151-12163.
18. Ogert RA, et al. 2010. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N terminus and ECL2 of CCR5. Virology 400:145-155.
19. Pfaff JM, et al. 2010. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+T cells. J. Virol. 84:6505-6514.
20. Putcharoen O, et al. 2011. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug. J. Virol. 86:1119-1128.
21. Roche M, et al. 2012. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage-tropism. J. Virol. 85:4330-4342.
22. Tilton JC, et al. 2010. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res. Hum. Retroviruses 26:13-24.
23. Tilton JC, et al. 2010. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84:10863-10876.
24. Tsibris AM, Kuritzkes DR. 2007. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58:445-459. (Pubitemid 46706526)
25. Tsibris AM, et al. 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 82:8210-8214.
26. Westby M, et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81: 2359-2371.
27. Wilkin TJ, et al. 2010. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 54:470-476.
28. Yusa K, Maeda Y, Fujioka A, Monde K, Harada S. 2005. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J. Biol. Chem. 280:30083-30090. (Pubitemid 41216184)